As Blockbusters go off patent and the pool of marketed products supporting pharmaceutical Research & Development (R&D) decline, questions about the future of R&D in the pharmaceutical and biotech industry arise. Where will funding come from? Is spend decreasing? If spend is decreasing, what impact is this having on R&D? What can be done to encourage innovation in the biotech and pharmaceutical industry? Is the biotech model of R&D better for innovation than the traditional pharmaceutical model?

Gauging the overall growth of R&D in the pharmaceutical and biotech industry proves challenging in regards to stipulating the appropriate definition of variables by which this is measured. Public companies may release overall expenses, yet allocations to specific products or franchises may be more difficult to assess. On a related note, information may be available about specific research projects and molecules under development, yet tying those back to the overall R&D expenses can also be challenging. To that end, we are focused on general estimations in this report which address a high level analysis of the overall industry and a basic formulaic approach to understanding growth and productivity within R&D. The methods used for assessing these variables are suppo180-180rted by literature in the field.

Browse Here For Full Report :

Research & Development (R&D) in the Pharmaceutical and Biotech Industry has experienced a major shift from the blockbuster era of the last decade. Pharmaceutical manufacturers are operating with thinner margins and smaller pipelines, the success rates of early stage research projects have decreased, and overall the complexity of efficient and productive R&D in the pharmaceutical industry has increased. This report provides an overview of the current situation in pharmaceutical and biotech R&D.


  • Current scenario of R&D
  • Review of the pipeline and key issues affecting R&D efforts
  • Approvals by year and by sponsor (established vs. new companies)
  • Trends in R&D spending
  • Analysis of R&D productivity
  • Company snapshots

Click Here For Same Category Reports :

Key Reasons to Purchase

  • Understand the current state of R&D in the biopharmaceutical industry and the key issues that are affecting companys efforts
  • Assess the strategies being used to strengthen R&D productivity and relate them to what is taking place within your organization
  • Evaluate how the top pharmaceutical and biotech companies have structured their pipeline
    Analyze the trends being seen in R&D spend and how different forms of collaboration could support a stronger R&D organization
  • Examine the R&D landscape and identify the key disease areas seeing the greatest activity
  • Benefit from CBRs insights & case study analysis to support a better understanding of different influencers of R&D productivity and the strategies which can be used within your organization

Request For Free Sample of This report :

About Us :
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products,establishments and trends. Our database consists of 200,000+ market research report s with detailed & minute market research.
Chris Paul
Office No 01, 1st Floor,
Aditi Mall, Baner, Pune,
MH, 411045 India
Phone (INDIA): +91 7755981103
Toll Free(US/CANADA):+1-855-455-8662
Website: Acute Market Reports